Melanoma cell therapy

Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme

Anna Laurenzana, Alessio Biagioni, Silvia D'Alessio, Francesca Bianchini, Anastasia Chillà, Francesca Margheri, Cristina Luciani, Benedetta Mazzanti, Nicola Pimpinelli, Eugenio Torre, Silvio Danese, Lido Calorini, Mario Del Rosso, Gabriella Fibbi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss of invasion properties and angiogenesis. MMP12 can be employed in the field of "targeted therapies" as a biological drug to be delivered directly in patient's tumor mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor and could be used as cellular vehicles for delivering anti-cancer molecules. The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor angiogenesis and development of lung metastasis. The possibility to exploit tumor homing and activity of autologous MMP12-engineered ECFCs represents a novel way to combat melanoma by a "personalized therapy", without rejection risk. The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new theranostic approach to control melanoma progression and metastasis.

Original languageEnglish
Pages (from-to)3711-3727
Number of pages17
JournalOncotarget
Volume5
Issue number11
Publication statusPublished - 2014

Fingerprint

Enzyme Activators
Urokinase-Type Plasminogen Activator
Cell- and Tissue-Based Therapy
Melanoma
Peptide Hydrolases
Neoplasms
Endothelial Progenitor Cells
Urokinase Plasminogen Activator Receptors
Neoplasm Metastasis
Lentivirus
Morphogenesis

Keywords

  • Cell-therapy
  • Endothelial progenitor cells
  • Melanoma
  • MMP12
  • uPAR

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Laurenzana, A., Biagioni, A., D'Alessio, S., Bianchini, F., Chillà, A., Margheri, F., ... Fibbi, G. (2014). Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget, 5(11), 3711-3727.

Melanoma cell therapy : Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. / Laurenzana, Anna; Biagioni, Alessio; D'Alessio, Silvia; Bianchini, Francesca; Chillà, Anastasia; Margheri, Francesca; Luciani, Cristina; Mazzanti, Benedetta; Pimpinelli, Nicola; Torre, Eugenio; Danese, Silvio; Calorini, Lido; Del Rosso, Mario; Fibbi, Gabriella.

In: Oncotarget, Vol. 5, No. 11, 2014, p. 3711-3727.

Research output: Contribution to journalArticle

Laurenzana, A, Biagioni, A, D'Alessio, S, Bianchini, F, Chillà, A, Margheri, F, Luciani, C, Mazzanti, B, Pimpinelli, N, Torre, E, Danese, S, Calorini, L, Del Rosso, M & Fibbi, G 2014, 'Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme', Oncotarget, vol. 5, no. 11, pp. 3711-3727.
Laurenzana A, Biagioni A, D'Alessio S, Bianchini F, Chillà A, Margheri F et al. Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget. 2014;5(11):3711-3727.
Laurenzana, Anna ; Biagioni, Alessio ; D'Alessio, Silvia ; Bianchini, Francesca ; Chillà, Anastasia ; Margheri, Francesca ; Luciani, Cristina ; Mazzanti, Benedetta ; Pimpinelli, Nicola ; Torre, Eugenio ; Danese, Silvio ; Calorini, Lido ; Del Rosso, Mario ; Fibbi, Gabriella. / Melanoma cell therapy : Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. In: Oncotarget. 2014 ; Vol. 5, No. 11. pp. 3711-3727.
@article{0dcee4acc9c344c1aefa67a8ec9e58f8,
title = "Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme",
abstract = "The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss of invasion properties and angiogenesis. MMP12 can be employed in the field of {"}targeted therapies{"} as a biological drug to be delivered directly in patient's tumor mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor and could be used as cellular vehicles for delivering anti-cancer molecules. The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor angiogenesis and development of lung metastasis. The possibility to exploit tumor homing and activity of autologous MMP12-engineered ECFCs represents a novel way to combat melanoma by a {"}personalized therapy{"}, without rejection risk. The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new theranostic approach to control melanoma progression and metastasis.",
keywords = "Cell-therapy, Endothelial progenitor cells, Melanoma, MMP12, uPAR",
author = "Anna Laurenzana and Alessio Biagioni and Silvia D'Alessio and Francesca Bianchini and Anastasia Chill{\`a} and Francesca Margheri and Cristina Luciani and Benedetta Mazzanti and Nicola Pimpinelli and Eugenio Torre and Silvio Danese and Lido Calorini and {Del Rosso}, Mario and Gabriella Fibbi",
year = "2014",
language = "English",
volume = "5",
pages = "3711--3727",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "11",

}

TY - JOUR

T1 - Melanoma cell therapy

T2 - Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme

AU - Laurenzana, Anna

AU - Biagioni, Alessio

AU - D'Alessio, Silvia

AU - Bianchini, Francesca

AU - Chillà, Anastasia

AU - Margheri, Francesca

AU - Luciani, Cristina

AU - Mazzanti, Benedetta

AU - Pimpinelli, Nicola

AU - Torre, Eugenio

AU - Danese, Silvio

AU - Calorini, Lido

AU - Del Rosso, Mario

AU - Fibbi, Gabriella

PY - 2014

Y1 - 2014

N2 - The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss of invasion properties and angiogenesis. MMP12 can be employed in the field of "targeted therapies" as a biological drug to be delivered directly in patient's tumor mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor and could be used as cellular vehicles for delivering anti-cancer molecules. The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor angiogenesis and development of lung metastasis. The possibility to exploit tumor homing and activity of autologous MMP12-engineered ECFCs represents a novel way to combat melanoma by a "personalized therapy", without rejection risk. The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new theranostic approach to control melanoma progression and metastasis.

AB - The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss of invasion properties and angiogenesis. MMP12 can be employed in the field of "targeted therapies" as a biological drug to be delivered directly in patient's tumor mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor and could be used as cellular vehicles for delivering anti-cancer molecules. The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor angiogenesis and development of lung metastasis. The possibility to exploit tumor homing and activity of autologous MMP12-engineered ECFCs represents a novel way to combat melanoma by a "personalized therapy", without rejection risk. The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new theranostic approach to control melanoma progression and metastasis.

KW - Cell-therapy

KW - Endothelial progenitor cells

KW - Melanoma

KW - MMP12

KW - uPAR

UR - http://www.scopus.com/inward/record.url?scp=84903533901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903533901&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 3711

EP - 3727

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -